中西药物结合治疗慢性阻塞性肺疾病急性加重期患者
李光
【期刊名称】《中华全科医师杂志》 【年(卷),期】2008(007)001
【摘要】对80例COPD急性加重期伴肺动脉高压患者均予西药常规治疗,治疗组40例加用参芎注射液静脉滴注,观察14 d,检测两组患者治疗前后肺动脉平均压、血小板α颗粒膜蛋白、血栓素B2、6-酮-前列腺素F1α的变化.与治疗前及对照组比较,参芎注射液静脉滴注能降低肺动脉平均压,明显增加6-酮-前列腺素F1α含量,降低血小板α颗粒膜蛋白、血栓素B2的含量,差异均有统计学意义.说明参芎注射液能抑制血小板活化功能,起到降低肺动脉高压的作用.%Eighty patients with acute exacerbation of chronic obstructive pulmonary disease(COPD)complicated by pulmonary artery hypertention(PAH)were recruited in the study. All patients took conventional western medicine, among them 40 also received injection of Chinese herb medicine Shenxiong(study group)for 14 days. Mean pulmonary artery pressure(mPAP), plasma platelet alphagranule membrane protein(GMP-140),
thromboxane
B2(TXB2)and
6-keto-prostaglandin
F1α(6-K-
PGF1α)were measured before and after treatment in both groups. Compared with pretreatment levels and levels in control group mPAP, GMP-140 and TXB2 levels in study group were significantly decreased, while the levels of 6-K-PGF1α were significantly increased. The results indicate that Shenxiong injection may inhibit platelet activation and
中西药物结合治疗慢性阻塞性肺疾病急性加重期患者
